Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. by de Souza, J Brian et al.
Brian de Souza, J; Hafalla, JC; Riley, EM; Couper, KN (2009) Cere-
bral malaria: why experimental murine models are required to under-
stand the pathogenesis of disease. Parasitology, 137 (5). pp. 755-72.
ISSN 0031-1820
Downloaded from: http://researchonline.lshtm.ac.uk/4375/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
REVIEW ARTICLE
Cerebral malaria: why experimental murine models are
required to understand the pathogenesis of disease
J. BRIAN DE SOUZA1,2, JULIUS C. R. HAFALLA1, ELEANOR M. RILEY1
and KEVIN N. COUPER1*
1 Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
Keppel Street, London WC1E 7HT, UK
2Department of Immunology and Molecular Pathology, University College London Medical School, 46 Cleveland Street,
London W1T 4JF, UK
(Received 14 September 2009; revised 20 October 2009; accepted 26 October 2009; ﬁrst published online 23 December 2009)
SUMMARY
Cerebral malaria is a life-threatening complication of malaria infection. The pathogenesis of cerebral malaria is poorly
deﬁned and progress in understanding the condition is severely hampered by the inability to study in detail, ante-mortem,
the parasitological and immunological events within the brain that lead to the onset of clinical symptoms. Experimental
murine models have been used to investigate the sequence of events that lead to cerebral malaria, but there is signiﬁcant
debate on the merits of these models and whether their study is relevant to human disease. Here we review the current
understanding of the parasitological and immunological events leading to human and experimental cerebral malaria,
and explain why we believe that studies with experimental models of CM are crucial to deﬁne the pathogenesis of the
condition.
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INTRODUCTION
Malaria remains a major public health problem in
many tropical countries. The World Health Organ-
ization (WHO) estimates that 40% of the world’s
population lives in areas aﬀected by malaria, result-
ing in approximately 200–300 million clinical cases
each year, leading to the deaths of more than
2 million young children every year, mainly in sub-
Saharan Africa. The vast majority of cases of severe
malaria are caused by infection with the Plasmodium
falciparum species of the parasite. Clinical presen-
tations of severe malaria vary but include altered
consciousness, respiratory distress, severe anaemia
(haemoglobin level of <5 g/dl), multi-organ failure
and cerebral malaria. The WHO deﬁnition of CM
is unrousable coma (graded according to either
Blantyre or Glasgow coma scale) not attributable to
other causes (Teasdale and Jennet, 1974; Molyneux
et al. 1989). In areas of high malaria transmission,
susceptibility to severe malaria varies with age and
exposure to the parasite; adults are, in general,
resistant to severe malaria whilst infants and very
young children are at signiﬁcantly increased risk of
developing severe malarial anaemia. Older children,
who have had at least one previous malaria infection,
are disproportionately at risk of developing cerebral
malaria (CM) (Marsh and Snow, 1999). The epi-
demiology of severe malaria is highly suggestive of a
role for the immune system in both initiation of
(in children) and protection from (in adults) cerebral
malaria, either indirectly – by selecting for infection
by parasites of diﬀering virulence – or directly – by
contributing to the pathogenesis of the syndrome.
CEREBRAL MALARIA
The incidence of cerebral malaria is diﬃcult to as-
sess, but hospital admission records indicate that
in the region of 1% of all P. falciparum infections
progress to CM, which is fatal in 10–20% of all cases
(300 000–500000 deaths each year). Moreover, at
least 10–20% of individuals who survive and recover
from CM display long-term physical or cognitive
dysfunction (Carter et al. 2005a, b ; Idro et al. 2005;
Boivin et al. 2007). Since the discovery by
Marchiafava and Bignami in 1894 of malaria para-
sites within the brain of humans during infection,
attention has focussed on understanding the patho-
physiological processes that predispose towards
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CM, with a view to the development of preventative
measures or targeted therapies for the condition.
Contrasting theories on the roles of parasite seques-
tration within the brain and the host immune re-
sponse to the parasite in the pathogenesis of CM
were initially proposed (reviewed by Van der Heyde
et al. 2006), with current understanding suggesting
that neuropathology is the result of a combination of
both processes, as discussed below.
Cerebral malaria can develop rapidly after initial
bouts of fever lasting 2–3 days. Coma is the standard
deﬁnition of CM, but other symptoms associated
with the condition include general malaise, head-
ache, ﬁts, vomiting and diarrhoea. The clinical
symptoms associated with early-stage CM are not
pathognomonic for the condition and are diﬃcult
to diﬀerentiate from encephalitis, meningitis and
febrile convulsions. This has implications for the
rapid and early diagnosis of the condition, which
often signiﬁcantly delays the initiation of treatment.
The early symptoms of CM can progress rapidly to
increased intracranial pressure, hemiparesis, ataxia
and coma if immediate medical treatment is not
provided. The diverse set of neurological complica-
tions associated with CM indicates that multiple
areas of the brain are aﬀected by the condition.
Anti-malarial drug-based therapies are the ﬁrst-
line treatment for patients with cerebral malaria ;
however, the incidence of neurological deﬁciencies
and mortality remain unacceptably high with fatal-
ity rates of around 15% following treatment with
Artemisinin compared with 20% for traditionally
used quinine-based treatments (Dondorp et al.
2005a). This is unsurprising as anti-malarial therapy
can only be implemented when CM is ﬁrst suspected
or diagnosed at health care centres ; CM is at an
advanced state in the majority of these individuals
and anti-malarial drugs by themselves are often in-
suﬃcient to reverse and alleviate the symptoms of
CM. Therefore, there is an urgent need to develop
adjunctive therapies, such as immuno-modulators or
neuro-protective agents that may be administered
with anti-malarials. At present the lack of under-
standing of the pathogenesis of CM means that the
potentially most eﬃcacious targets for therapeutic
intervention remain to be identiﬁed.
THE PATHOLOGY AND ASSOCIATED CLINICAL
FEATURES OF CM
Post-mortem examinations of brains from indivi-
duals that succumbed to CM have helped to uncover
the type and distribution of brain pathology that
occurs during the condition. Some of the most
commonly reported ﬁndings include swelling and
haemorrhaging in the white matter of the subcortical
rim and corpus callosum as well as petechial and
ring haemorrhages in both cerebral and cerebellar
cortices (reviewed by Haldar et al. 2007). In the
majority of cases, histopathological examinations
reveal cerebral capillaries plugged with parasitized
erythrocytes (reviewed by Haldar et al. 2007).
Margination of monocytes and macrophages within
cerebral vessels and the presence of pigmented
macrophages sequestered with pRBC are also well
described features of CM (Patnaik et al. 1994). Due
to the lack of detailed comparative histopathological
studies of pediatric and adult CM cases it is diﬃcult
to conclude whether the pathology of CM varies
between children and non-immune adults, but as
there are a number of diﬀerences in the symptoms of
pediatric and adult CM, it is possible there may be
some age-related diﬀerences in cerebral pathology
(Mishra and Wiese, 2009).
Although parasite sequestration, haemorrhages
and inﬂammation are found in the majority of CM
brains, it is clear that CM is not a homogenous syn-
drome. For example, 3 diﬀerent patterns of histo-
pathological changes have been described in African
children: in addition to the ‘classical ’ pattern of
CM of parasite sequestration, perivascular haemor-
rhages and immune cell inﬁltration within brain
micro-vessels, parasite sequestration may be obser-
ved within the brain in the absence of any other ab-
normalities and there are cases where individuals
with high peripheral parasitaemia develop a syn-
drome that is clinically deﬁned as CM but where
there is no evidence of parasite sequestration within
the brain (Clark et al. 2003; Taylor et al. 2004). The
reasons for the variations in pathology of CM are
unclear but may be due to genetic variation in hosts
or parasites, environmental factors or the host im-
mune response to the parasite.
THE LIMITATIONS OF STUDIES OF HUMAN
CEREBRAL MALARIA IN DEFINING THE
PATHOGENESIS OF THE CONDITION
Cerebral malaria is likely the result of a complex
sequence of inter-related events, most probably
beginning either with sequestration of trophozoite-
infected red blood cells (pRBC) in the small blood
vessels (reviewed by Chakrovorty et al. 2008) and/or
with the rupture of infected red blood cells and
the release of parasite-derived toxins (Bate and
Kwiatkowski, 1994; Schoﬁeld et al. 1996). The re-
lative importance of systemic versus brain-localized
events – including pRBC sequestration and rupture,
lymphocyte, monocyte, endothelial and glial cell
activation and release of inﬂammatory mediators –
their sequence and timing in the pathogenesis of
CM are very much unknown. For obvious reasons,
histopathological examination of CM brains is
limited to post-mortem analysis of fatal cases and it
is thus not possible to describe the sequence of events
leading to the onset of CM symptoms nor to com-
pare fatal cases with those that resolve in response to
treatment. Such investigations and comparisons are
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essential to delineate truly pathogenic systemic and
intra-cerebral processes from neutral and/or pro-
tective responses. Increased utility of non-invasive
in vivo imaging techniques, such as magnetic reson-
ance imaging (MRI) and spectroscopy (MRS) and
computational topography (CT), should hopefully
help to address these issues (Kampﬂ et al. 1993;
Crawley et al. 1996; Patanker et al. 2002; Penet et al.
2005, 2007), but these studies are severely restricted
by ethical constraints and the availability of the
expensive specialized equipment in malaria-endemic
areas. It is therefore extremely diﬃcult to move be-
yond purely descriptive and correlative studies in
humans: deﬁning the immunological pathways and
parasite-driven processes that underlie the patho-
genesis of the syndrome, and demonstrating caus-
ality, is diﬃcult without direct intervention studies.
Moreover, examination of peripheral blood (which is
possible in non-fatal as well as fatal cases) may pro-
vide limited information on the immunological and
parasitological environment in the brain and, again,
patients usually present to hospital only once the
syndrome is well-established. For example, periph-
eral blood parasitaemia does not always accurately
predict total parasite biomass (Silamut et al. 1999)
and total parasite biomass is a stronger correlate of
severe malarial disease than is peripheral parasita-
emia (Dondorp et al. 2005b). It is clear that other
approaches – in combination with human studies –
are required to fully understand the pathogenesis
of CM.
EXPERIMENTAL MODELS OF CEREBRAL MALARIA
Much of our understanding of mammalian physi-
ology has come from studies of animals and the
extent of the conservation of basic immunological
and neuropathological processes between laboratory
rodents and humans is becoming ever more apparent
(Hau and Van Hoosier Jr, 2005). Experimental
models have proven invaluable for understanding
the pathogenesis of numerous autoimmune and in-
fectious diseases of humans and many vaccines and
immune-therapies currently in use were initially
developed and tested in experimental models (Hau
and Van Hoosier Jr, 2005). It is likely, therefore,
that the use of relevant experimental animal models
can signiﬁcantly aid in the study of cerebral malaria.
Primate models of CM, including P. knowlesi and
P. coatneyi infections in Rhesus monkeys (Aikawa
et al. 1992; Ibiwoye et al. 1993) and P. falciparum
infection in squirrel monkeys (Gysin et al. 1992),
have allowed the investigation of some aspects of
CM, but these models are prohibitively expensive
and are restricted to low numbers for ethical reasons.
Consequently, other experimental models are re-
quired. Neuropathological syndromes have been
shown to develop in certain strains of inbred mice
infected with various strains of Plasmodium berghei
(Pb) (Rest, 1982; Curfs et al. 1993a) or the
lethal (XL) variant of P. yoelii (PyXL) (Yoeli and
Hargreaves, 1974) ; however, there has been – and
continues to be – signiﬁcant disagreement within the
malaria research community as to whether the mu-
rine models share suﬃcient similarities with human
cerebral malaria to make them relevant or useful.
In the remainder of this review we will evaluate
the currently available models of ECM and we will
attempt to resolve the relevance of experimental
models of cerebral malaria to human infection.
Plasmodium yoelii XL and Plasmodium
berghei K173
Although more extensively studied as a model of
hyperparasitaemia and failure of parasite control
(Couper et al. 2007, 2008), PyXL has been shown to
sequester within the brain microvasculature and
produce a cerebral syndrome comparable with hu-
man cerebral malaria (Yoeli and Hargreaves, 1974;
Kaul et al. 1994); however, the hyper-parasitaemia
associated with this infection (rapidly ascending
peripheral parasitaemia that can reach 80–100%) is
not typical of human CM cases (Silamut et al. 1999)
and this model is not widely used to study CM. In a
few studies, P. berghei K173 has been found to
induce CM-like signs (Curfs et al. 1993a ; Mitchell
et al. 2005), but the dose-dependent onset of ECM
in this model (inducing cerebral pathology after low
dose but not high dose infection) (Mitchell et al.
2005) also limits its utility as a model of human CM:
indeed P. berghei K173 is frequently used as a non-
ECM-infection to compare with the most widely
used model of ECM, P. berghei ANKA infection
(Mitchell et al. 2005).
Plasmodium berghei ANKA
The Plasmodium berghei ANKA (PbA) model re-
plicates many events seen during human CM and
is accepted as the best available experimental model
of cerebral malaria. Infection of susceptible strains
of mice, including C57BL/6 and CBA, leads to the
development of fatal cerebral pathology, with clini-
cal signs including ataxia, ﬁtting, respiratory distress
and coma (de Souza and Riley, 2002). The time to
onset of clinical signs varies depending on the in-
fection dose, the genetic background of the host and
the speciﬁc clone of infecting parasites, but is typi-
cally between 5 and10 days post-infection (de Souza
and Riley, 2002). As in humans, there is a rapid de-
terioration in the condition of infected animals once
clinical signs become apparent, with death often oc-
curring within 4 or 5 h after the onset of neurological
signs. Multiple areas of blood-brain barrier disrup-
tion with vascular leakage involving the cortex, cer-
ebellum and olfactory bulb are observed in brains
of PbA-infected mice displaying signs of ECM
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(Penet et al. 2005; Lackner et al. 2006; de Souza
and Couper, unpublished observations), with loss of
speciﬁc neuronal populations within the cortex and
striatum (Clark et al. 2005), accumulation of pRBC
within blood vessels (Rest, 1982; Hearn et al. 2000)
and focal perivascular inﬂammation (Engwerda et al.
2002). ECM is also associated with the signiﬁcant
accumulation of platelets within the brain vascu-
lature (Wassmer et al. 2003; von Zur Muhlen et al.
2008): platelets have been shown to directly promote
endothelial cell damage during infection (Wassmer
et al. 2006). Cognitive dysfunction during P. berghei
ANKA infection, as shown by impaired visual
memory, is directly correlated with haemorrhage
and inﬂammation, including microglial activation
(Desuisseaux et al. 2008). Indeed, accumulation of
monocytes and macrophages, and activation of brain
resident mononuclear cells, including astrocytes and
microglial cells is believed to be a key feature of
ECM (Grau et al. 1987; Medana et al. 1997a, b ; Pais
and Chatterjee, 2005) (Fig. 1).
As in humans, genetic and environmental factors
determine the susceptibility of mice to ECM. For
example, the resistance of F1 intercrossed BALB/c
(resistant) and C57BL/6 (susceptible) mice to the
development of ECM is determined by age, and
environmental exposure, with young mice (8–10
weeks) susceptible to ECM and older mice (16–20
weeks) resistant to the development of cerebral signs
(Hearn et al. 2000). Genetic resistance to ECM
and P. berghei ANKA infection has been mapped
using intercrossed resistant and susceptible strains
of mice to loci on chromosomes 1, 9, 11, 17 and 18
(Bagot et al. 2002; Nagayasu et al. 2002; Ohno and
Nishimura, 2004; Campino et al. 2005). However,
the genes encoded within each of these regions that
control resistance to ECM and parasite levels remain
to be identiﬁed.More recently, micro-array proﬁling
Fig. 1. A hypothetical schema of events leading to the development of experimental cerebral malaria. Rupture of
pRBCs releases molecules that activate brain microvascular endothelial cells leading to upregulation of receptors for
pRBC. Phagocytosis of parasite moieties in the spleen and liver, priming lymphocytes within the spleen, promotes
systemic inﬂammation which further ampliﬁes endothelial cell activation in the brain and activates brain-resident
perivascular macrophages, microglia and astrocytes. pRBCs bind to endothelial receptors ; platelets binding to
endothelial receptors may provide additional ligands for pRBC adherence. Activated endothelial and glial cells provide
chemotactic signals for lymphocytes and myeloid cells. Sequestered pRBCs and leukocytes interfere with cerebral blood
ﬂow and, together with cytotoxic molecules, damage the blood-brain barrier leading to oedema and haemorrhage.
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of susceptible and resistant strains of mice have
identiﬁed distinct expression proﬁles in the brain
of genes involved in metabolic energy pathways,
immune-activation, apoptosis and neuroprotection/
neurotoxicity (Delahaye et al. 2007; Lovegrove et al.
2007; Oakley et al. 2008). Diﬀerences in the immune
response of ECM-susceptible and ECM-resistant
strains of mice to infection are discussed in more
detail below.
THE ROLE OF PARASITE SEQUESTRATION
DURING HUMAN AND EXPERIMENTAL CEREBRAL
MALARIA
The sequestration of mature parasites within peri-
pheral tissues via adherence of pRBC to vascular
endothelium is a common feature of malaria infec-
tions. It is believed that this prevents the clearance
of mature-stage parasites by the spleen, allowing
the development of suﬃcient numbers of infectious
parasites (gametocytes) to ensure transmission to
mosquitoes (Beeson et al. 2001; Engwerda et al.
2005). Although sequestration is initially beneﬁcial
to the parasite, it is widely believed to have signiﬁ-
cant deleterious consequences for the host. For
many years it was assumed that the symptoms of
CM were due solely to occlusion of brain micro-
vessels by sequestered pRBC (reviewed by Berendt
et al. 1994; Van der Heyde et al. 2006). In this
scenario, parasite adherence to brain endothelial
cells, combined with rosetting of uninfected and
infected red blood cells, impairs blood ﬂow leading
to hypoxia, hypoglycaemia and the buildup of toxic
waste products, including lactic acid (Van der Heyde
et al. 2006), which rapidly leads to irreversible tissue
damage. However, the typically quite subtle neuro-
logical consequences experienced by CM survivors
are not consistent with this simple aetiology and
other causes of disrupted neuronal signalling are also
likely to play a part (Rae et al. 2004; Penet et al.
2005; Hunt et al. 2006).
Although parasite sequestration is usually seen in
CM brains, the association is not absolute and, de-
spite a plethora of associative data, there is very little
empirical evidence that parasite sequestration in
the brain is either necessary or suﬃcient to cause
CM. Deaths attributable to CM, as deﬁned byWHO
guidelines, have been observed in the absence of
parasite sequestration within the brain (Clark et al.
2003; Taylor et al. 2004; Haldar et al. 2007).
Furthermore, parasite sequestration has been ob-
served in individuals that did not develop severe
cerebral malaria (Silamut et al. 1999; Seydel et al.
2006). This heterogeneous association between cer-
ebral parasite sequestration and clinical outcome
raises important questions regarding the precise
aetiology of CM (Clark et al. 2006). Speciﬁcally, we
need to consider the possibility that transient inter-
actions between sequestering pRBC and cerebral
tissues might be suﬃcient to trigger downstream
immunological and biochemical processes that lead
to the development of CM.
The widespread assumption that sustained para-
site sequestration in the brain is essential for devel-
opment of CM has led some researchers to question
whether cerebral parasite sequestration occurs dur-
ing P. berghei ANKA infection and thus whether
the pathogenesis of ECM is comparable to human
CM (Berendt et al. 1994; Franke-Fayard et al.
2005). Accumulation of PbA pRBCs in cerebral and
cerebellar capillaries of mice displaying signs of
ECM has been observed at both light and electron
microscopic levels (Rest, 1982; Jennings et al. 1998;
Hearn et al. 2000; Beghdadi et al. 2008). Detailed
investigations on the nature of parasite sequestration
during P. berghei ANKA infection have, however,
yet to be performed and as such it is unknown
whether PbA parasites adhere through strong, tight
junctions, or via weak easily disrupted interactions.
The comparison of parasite sequestration in the
brain during ECM and CM is also severely compli-
cated by the method of tissue preparation; mouse
brains are routinely perfused prior to histological
examination during ECM, but perfusion is seldom
performed prior to the examination of brains from
individuals with fatal CM. As such, parasite seques-
tration may be frequently under-estimated (in ECM)
or over-estimated (in CM). Nevertheless, most
blocked vessels during ECM contain a mixture of
parasitized RBC and leukocytes (Hearn et al. 2000;
Jennings et al. 1998). Consequently, parasite ac-
cumulation alone may not be suﬃcient to cause
blockage of brain-micro-vessels during P. berghei
ANKA infection.
Recently, Franke-Fayard et al. (2005) reported
CD36 (Scavenger type B receptor)-mediated seq-
uestration of luciferase-expressing P. berghei ANKA
pRBC, visualized by bioluminescent imaging, in
lung and adipose tissue but not in the brains of in-
fected mice. This is consistent with the requirement
for CD36-mediated PbA pRBC sequestration for
initiation of acute lung injury (Lovegrove et al.
2008), and with the observation that CD36x/x mice
are fully susceptible to ECM. These ﬁndings have
been interpreted as evidence that pRBC seques-
tration does not occur in the brain during PbA in-
fection and is not required for initiation of ECM,
and thus that ECM has a signiﬁcantly diﬀerent
aetiology to CM (Franke-Fayard et al. 2005). How-
ever, whole body imaging and multi-organ com-
parisons may under-estimate cerebral sequestration
since it is likely that the density of sequestered
pRBC is much lower in brain than in much more
heavily vascularized organs such as lung or spleen,
and higher resolution analysis of the brain is re-
quired to rule out sequestration; nevertheless, and
despite the authors claims, focal parasite seques-
tration was evident in one of the two examples of day
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7 p.i. brains shown by Franke-Fayard et al. (2005).
Secondly, the lack of a role for CD36 in ECM does
not rule out that (as in humans) there are other re-
ceptors mediating pRBC sequestration in the brain
(as discussed below). Importantly, other studies
using the same bioluminescent parasite system
have not only shown signiﬁcant accumulation of P.
berghei ANKA pRBC in the brains of mice showing
signs of ECM, but have also demonstrated that
parasite biomass in the brain is directly correlated
with risk of ECM (Amante et al. 2007; Randall et al.
2008a ; Nie et al. 2009).
HOST CELL RECEPTORS MEDIATING
CYTO-ADHERENCE DURING CM AND ECM
Although CD36 appears to be the main receptor for
P. falciparum pRBC sequestration in peripheral or-
gans, CD36-mediated adhesion is not believed to be
involved in sequestration in the brain (Newbold et al.
1999); CD36 is expressed only at very low levels in
healthy brain tissue and it is not upregulated during
malaria infection (Turner et al. 1994; Newbold et al.
1999). Nonetheless, it has recently been postulated
that platelets and platelet and endothelial cell de-
rived microparticles – submicron particles generated
by vesiculation of cellular membranes (reviewed by
Coltel et al. 2006) – may bind to brain endothelial
cells, providing a source of CD36 that allows in-
direct CD36-mediated pRBC binding to brain en-
dothelial cells (Wassmer et al. 2004; Faille et al.
2009); however, this hypothesis remains to be vali-
dated in vivo.
At present, intercellular adhesion molecule 1
(ICAM-1) is the most studied putative endothelial
receptor for the sequestration of P. falciparum pRBC
within the brain (Newbold et al. 1999; Chakravorty
and Craig, 2005). The expression of ICAM-1 is
signiﬁcantly upregulated on cerebral vasculature
endothelium during malaria infection (Turner et al.
1994; Newbold et al. 1999), and P. falciparum pRBC
bind to ICAM-1 in vitro under ﬂow conditions
(Ockenhouse et al. 1991, Udomsangpetch et al. 1996;
Adams et al. 2000). Strains of P. falciparum diﬀer in
their ability to bind to ICAM-1 and CD36 (Johnson
et al. 1993; Gardner et al. 1996; Udomsangpetch
et al. 1996) and although there is some evidence that
the degree of binding of pRBC to ICAM-1 is associ-
ated with risk of development of CM (Newbold et al.
1999), this correlation is not absolute (Rogerson et al.
1999; Heddini et al. 2001). Moreover, there are
conﬂicting data on links between risk of CM and
allelic variation in the ICAM-1 gene. Speciﬁcally, a
non-synonomous single nucleotide polymorphism in
ICAM-1 (ICAM-1 kiliﬁ) has been shown to be either
associated (Fernandez-Ryes et al. 1997), or not as-
sociated (Bellamy et al. 1998; Fry et al. 2008) with
the risk of severe malaria. Consequently, it has
been proposed that other receptors may facilitate
pRBC sequestration within the brain (Ockenhouse
et al. 1992; Chakravorty and Craig 2005). Up-
regulated expression of VCAM-1, E-Selectin and
ELAM-1 by brain microvascular endothelium is
also observed duringCM;however, aswith ICAM-1,
there is signiﬁcant debate on the role of these re-
ceptors (Ockenhouse et al. 1992; Silamut et al. 1999;
Udomsangpetch et al. 1996), which may reﬂect dif-
ﬁculties in comparing in vitro studies using plate-
bound receptors or (non-cerebral) endothelial cells
with what may occur in vivo during infection. The
failure to identify a single critical receptor mediating
pRBC sequestration in the brain during CM may
indicate promiscuous or redundant receptor binding
by the parasite. This ﬁts the current model where
P. falciparum cyto-adherence is a multi-step process
involving multiple (possibly partially redundant)
receptor interactions mediating primary contact,
rolling and ﬁnally ﬁrm adhesion (Udomsangpetch
et al. 1997; McCormick et al. 1997; Yipp et al. 2000;
Gray et al. 2003; Ho et al. 1998).
As in human CM, ICAM-1, VCAM-1 and P-
selectin are all upregulated on brain vascular endo-
thelium in ECM-susceptible strains of mice during
P. berghei ANKA infection (reviewed by Schoﬁeld
and Grau, 2005; Good et al. 2005). Moreover,
ICAM-1 deﬁcient mice (backcrossed onto the sus-
ceptible C57BL/6 background) do not develop
ECM, suggesting that ICAM-1 expression is an es-
sential step in the pathway of development of ECM
(Favre et al. 1999; Li et al. 2003). Leukocyte rolling
in these mice was unimpaired – indicating that re-
sistance to ECM was not due to decreased leukocyte
sequestration in the brain – but pRBC sequestration
within the brain was not speciﬁcally examined.
Similarly, mice with speciﬁc defects in endothelial
cell expression of P-selectin are also resistant to
ECM but, again, pRBC sequestration was not re-
ported (Combes et al. 2004). Clearly, more detailed
examinations of these mouse strains are required to
determine whether ECM resistance is due to re-
duced pRBC sequestration, attenuation of immune
responses (including suboptimal T cell activation)
or both.
PARASITE LIGANDS MEDIATING pRBC
SEQUESTRATION DURING CEREBRAL MALARIA
Clonally variant surface antigens that are expressed
on the surface of P. falciparum-infected erythrocytes
are known to facilitate binding of pRBC to endo-
thelial receptors (Newbold et al. 1999). The most
studied of these is the P. falciparum erythrocyte
membrane protein-1 (PfEMP-1) family of proteins.
Encoded by var genes, PfEMP-1 is a polymorphic,
high molecular weight (200–500 kDa) protein com-
prised of variable numbers and sequences of duﬀy
binding like (DBL) and cysteine-rich interdomain
region (CIDR) domains that mediate binding to
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various host molecules (reviewed by Scherf, 2008).
Infected erythrocytes from most P. falciparum iso-
lates bind to CD36 through its interaction with
CIDR-1 (Baruch et al. 1995, 1997). DBL-1a, with
its clusters of glycosaminoglycan (GAG)-binding
motifs, is believed to mediate the formation of ro-
settes (i.e. binding of infected erythrocytes to un-
infected erythrocytes) (Chen et al. 1998), which have
been linked to the pathogenesis of CM (Newbold
et al. 1999), whereas DBL-1b binds to ICAM-1
(Smith et al. 2000; Oleinikov et al. 2009) and DBLc
binds to chondroitin suphate A (CSA) (Reeder et al.
1999; Buﬀet et al. 1999; Gamain et al. 2004), the
latter interaction mediating tissue-speciﬁc seques-
tration of pRBC in the placenta. Disease association
studies have suggested that diﬀerences in CIDRs
and DBLs between commonly expressed var genes
may contribute to variations in parasite virulence
(Jensen et al. 2004; Normark et al. 2007), such that
some parasite isolates are more likely than others to
sequester in particular tissues and therefore cause
diﬀering clinical presentations, but – with the ex-
ception of particular PfEMP-1 molecules that favour
placental sequestration (Fried and Duﬀy, 2002;
Salanti et al. 2004) – direct evidence to support this
hypothesis is lacking. Moreover, the potential roles
in pRBC sequestration of other parasite-encoded
erythrocyte surface antigens such as stevors (subtelo-
meric variant open reading frame), riﬁns (repetitive
interspersed family of genes), Pfmc-2TM, surfs
(surface-associated interspersed genes), reticulocyte-
homologue binding proteins, EBA (erythro-
cyte binding antigen) and RhopH1/clag (high
molecular mass rhoptry complex/ cytoadherence
linked asexual gene) also need clariﬁcation (Scherf,
2008).
There are no known homologues of var genes in
other malaria species. However, a large multi-gene
Plasmodium interspersed repeat (pir) family has been
identiﬁed in P. vivax (del Portillo et al. 2001) and
is believed to be involved in antigenic variation.
Homologues members of the pir family have been
discovered in the rodent malaria parasites P. cha-
baudi (cir), P. yoelii (yir) and P. berghei (bir) (Carlton
et al. 2002; Janssen et al. 2002; Cunningham et al.
2005). Whilst clonal antigenic variation has been
described in P. chabaudi (McLean et al. 1986), the
role of the cir family remains to be determined.
Furthermore, whether the bir family plays a role in
the development of P. berghei-induced ECMmalaria
remains to be elucidated.
THE ROLE OF THE IMMUNE RESPONSE IN THE
PATHOGENESIS OF CEREBRAL MALARIA
Human cerebral malaria
The highly characteristic cytokine proﬁles that
are associated with acute severe malaria provide
associative evidence for involvement of the host im-
mune response in the aetiology of CM. High plasma
TNF, IFN-c, IL-6 concentrations and elevated
ratios of pro-to anti-inﬂammatory cytokines (in-
cluding IL-10) are consistently observed in indi-
viduals with cerebral malaria when compared with
individuals with uncomplicated malaria (reviewed
Schoﬁeld and Grau, 2005; Good et al. 2005) and
high concentrations of inﬂammatory cytokines in the
cerebrospinal ﬂuid are associated with a high risk of
developing neurological sequelae (John et al. 2008).
Very recently it has been shown that the binding
of pRBCs to brain endothelial cells, causes the
activation of the NF-kB pathway, leading to the
production of CCL20, CXCL1, CXCL2, IL-6 and
IL-8 (Tripathi et al. 2009). Despite this, the diﬃ-
culty of carrying out mechanistic studies in humans
means that it is not at all clear whether (and if so,
how) these inﬂammatory responses lead to the onset
of CM; however, direct eﬀects, such as upregulation
of endothelial ICAM-1 and VCAM-1 expression
(Esslinger et al. 1994), and indirect eﬀects, such as
induction of fever leading to enhanced expression of
PfEMP1 on pRBCs (Udomsangpetch et al. 2002),
either of which might potentiate pRBC seques-
tration, have been suggested. Inﬂammatory cyto-
kines may also be responsible for the presence of
activated microglial cells (Schluesener et al. 1998),
the main phagocytic macrophage-like cell popu-
lation of the brain, and sequestered monocytes
(Patnaik et al. 1994) in CM. It is possible that acti-
vated myeloid cells amplify the local intra-cerebral
inﬂammatory response – by presenting antigen to T
cells and/or producing inﬂammatory cytokines – but
deﬁnitive exploration of this pathway in human CM
is not feasible. The constraints imposed by gaining
access to crucial tissues at key time-points in the
onset of CM also explains the relative lack of data on
the role of T cells in human CM. The only data that
are available compare peripheral blood T cell popu-
lations in CM and non-CM cases and since it is clear
that there is major re-alloacation of T cell subsets
between the tissues and peripheral blood during
acute malaria infection (Elhassan et al. 1994), these
data are extremely diﬃcult to interpret. Neverthe-
less, reductions in numbers of circulating CD4+
T cells (reﬂecting either sequestration in tissues or
activation-induced cell death) (Elhassan et al. 1994;
Hviid et al. 1997) and increased frequencies of
CD4+ T cells expressing TCR Vb21.3 have been
correlated with disease severity (Loizon et al. 2007).
The potential for CD8+ T cells to play a role in the
aetiology of human CM has not been systematically
evaluated but there is no evidence as yet to implicate
this population in the pathogenesis of CM.
Further evidence that the immune response plays
a role in the pathogenesis of severe malaria comes
from a series of studies designed to identify genetic
polymorphisms that inﬂuence the risk of developing
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CM (Verra et al. 2009). Although there is a bias
within the literature towards publication of positive
associations the vast majority of reported associ-
ations involve genes that either aﬀect parasite
development within the red blood cell (e.g. haemo-
globinopathies) or that moderate the strength and
character of the immune response, for example
TNF gene promoter variants (Knight et al. 1999;
Cabantous et al. 2006; Clark et al. 2009) and inter-
feron regulatory factor-1 gene variants (Koch et al.
2002; Mangano et al. 2008, 2009). The details of
these associations vary from one population to an-
other, likely reﬂecting diﬀerences in genetic back-
ground, but a clear message is beginning to emerge
that is consistent with traits that lead to higher than
average inﬂammatory responses being linked to in-
creased risk of CM (Verra et al. 2009).
The idea that excessive pro-inﬂammatory im-
mune responses pre-dispose to CM is also consistent
with the clear age-related susceptibility to the de-
velopment of CM in malaria endemic areas: very
young children who have yet to acquire malaria-
speciﬁc cellular immune responses are relatively
resistant to CM (presenting instead with severe
malarial anaemia) whereas older children – in whom
previous malaria infections will have primed Th-1-
like adaptive immune responses – are at increased
risk of CM. Epidemiological studies suggest that
repeatedly exposed individuals eventually develop
protective immunity (such that adults in endemic
areas rarely develop CM), which may be charac-
terized by the ability to control parasite replication
(keeping parasite densities below the critical thresh-
old for induction of inﬂammation or impairment of
cerebral blood ﬂow), to prevent pRBC sequestration
or to regulate the inﬂammatory process (Artavanis-
Tsakonas et al. 2003; Walther et al. 2009).
Experimental cerebral malaria
The vast majority of the immunological features of
human CM are recapitulated during P. berghei
ANKA infection. For example, the susceptibility of
various inbred mouse strains to ECM has been di-
rectly correlated with the strength of the pro-inﬂam-
matory immune response to the parasite and to the
response of microglial and cerebral endothethelial
cells (e.g. upregulation of MHC Class I and Class II
molecules, ICAM-1 and VCAM-1) to these inﬂam-
matory mediators (Lou et al. 1998, 2001; Monso-
Hinard et al. 1997; Randall et al. 2008a). Moreover,
experimental manipulation of PbA-infected mice
has allowed causal relationships to be established
between speciﬁc immune responses and the devel-
opment of ECM; in the main these relationships are
entirely consistent with the associative observations
from human studies. For example, administration
of LPS, neutralization of IL-10 or heme oxygenase 1
or inhibition of CTLA-4 signalling during PbA
infection all lead to the development of ECM in
normally resistant mice (Kossodo et al. 1997; Neill
and Hunt, 1995; Pamplona et al. 2007; J. Hafalla
manuscript in preparation), whereas neutralization
or ablation of IFN-c, TNF and LT-a signalling
or depletion of macrophages (by administration of
clodronate liposomes) prevents the development of
ECM in susceptible mouse strains (Grau et al. 1987,
1989; Curfs et al. 1993b ; Rudin et al. 1997; Randall
et al. 2008b ; Engwerda et al. 2002; Amani et al.
2000; Togbe et al. 2008). Taken together, the wealth
of experimental data indicates that the balance of
Th-1 to T regulatory responses is critical in deter-
mining the outcome of PbA infection (Kossodo et al.
1997; Amante et al. 2007; Nie et al. 2007), whereas
manipulation of Th-2 responses (for example by
ablation of IL-4R signalling) does not substantially
aﬀect the outcome of infection (Saeftel et al. 2004).
As in humans, circulating cytokines seem to activate
cerebral endothelium, leading to increased expres-
sion of adhesion receptors, as well as upregulating
chemokine production and chemokine receptor ex-
pression on leukocytes (Lou et al. 1998; Schoﬁeld
and Grau, 2005; Good et al. 2005; Weiser et al.
2007) (Fig. 1).
It is well established that CD8+ T cells play an
essential role in the development of ECM: this has
recently been reviewed in detail elsewhere (Renia
et al. 2006). In summary, however, CD8+ T cells
accumulate in the brains of susceptible but not re-
sistant mice, in a CXCR3-, IP-10- (CXCL9), MIG-
(CXCL10) and platelet factor-4-dependent manner
(Hansen et al. 2007; Miu et al. 2008; Van Den Steen
et al. 2008; Campanella et al. 2008; Srivastava et al.
2008; Nie et al. 2009), immediately before the onset
of neurological signs, and are believed to directly
cause disruption of the blood-brain barrier and
endothelial cell damage via perforin production
(Nitcheu et al. 2003; Potter et al. 2006) (Fig. 1) :
depletion of CD8+ T cells either early (from start of
infection) or late (from day 4 or 5 post-infection)
in infection completely inhibits the development
of ECM (Yanez et al. 1996; Belnoue et al. 2002;
Hermsen et al. 1997). CD8+ T cells migrate to the
brain in a largely antigen-speciﬁc manner, following
cross-presentation of malaria antigens by classical
CD8+ dendritic cells (deWalick et al. 2007; Lundie
et al. 2008; Miyakoda et al. 2008). The recent
demonstration that NK cell-derived IFN-c is re-
quired for upregulation of CXCR3 on CD8+T cells
and for their subsequent migration to and accumu-
lation within the brain (Hansen et al. 2007) is con-
sistent with the observation that IFN-cR signalling
regulates sequestration of CD8+ T cells within the
brain in susceptible mice (Belnoue et al. 2008), and
reveals important interactions between innate and
adaptive immune responses in the pathogenesis of
ECM, opening up potential new avenues of research
into the role of innate immune responses, and of
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genetic variation in innate response genes, in the
pathogenesis of human CM.
It is clear that eﬀector CD4+ T cells also con-
tribute to the development ECM, potentially by
providing help to CD8+ T cells (Good et al. 2005) ;
thus, it has been shown that depletion of CD4+
T cells during the early (but not later) stages of
PbA infection prevents the development of ECM
(Belnoue et al. 2002). Nevertheless, in separate
studies, depletion of CD4+ T cells during the later
stages of infection also prevented the development of
ECM (Hermsen et al. 1997; Belnoue et al. 2008),
implying that although far fewer CD4+ than CD8+
T cells accumulate in ECM brains (Belnoue et al.
2002), CD4+ T cells may also be involved in the
eﬀector phase of ECM. On the other hand, adoptive
transfer of PbA-speciﬁc CD4+ T cells reduces par-
asite burdens and prevents ECM in semi-susceptible
mice (Finley et al. 1983). Whether the protective and
pathogenic functions of CD4+ T cells are mediated
by distinct subpopulations of Th cells, or is a
consequence of the cellular location and/or the
number of cells – all of which may potentially vary
within diﬀerent strains of inbred mice – requires
further investigation.
The above section clearly describes the associated
role of the pro-inﬂammatory immune response in
the pathogenesis of CM and ECM. Leukocyte ac-
cumulation within the brain is a signiﬁcant feature of
CM and ECM, but, intriguingly, transmigration of
leukocytes into the brain parenchyma does not ap-
pear to occur in either condition, indicating that
the immunopathogenesis of CM is diﬀerent from
other cerebral pathologies, including Experimental
Autoimmune Encephalitis and Multiple Sclerosis.
Signiﬁcantly more is understood regarding the im-
munological basis of ECM compared with human
CM, where the relatively few studies performed are
by necessity purely correlative. Consequently, it is
impossible at present to deﬁnitively state whether
the pathogenesis of CM is more or less immune-
mediated than ECM, and whether cells, such as
CD8+ T cells, play comparable roles in the devel-
opment of pathology in the two conditions. The
ECM model provides valuable clues to processes
that can lead to the development of pathology during
malaria infection (Fig. 1), and should help to direct
focused research to deﬁne the immunopathogenesis
of CM.
IF ECM IS SUCH A GOOD MODEL FOR HUMAN
CM WHY DO PREVENTIVE INTERVENTIONS
IDENTIFIED IN ECM FAIL TO REDUCE THE
MORBIDITY AND MORTALITY OF HUMAN CM?
The most important reason for developing a
good model of CM is to identify and test novel
therapies for prevention, attenuation or reversal of
cerebral pathology. It is therefore disappointing that
interventions, such as anti-TNF therapy (Grau et al.
1987) and dexamethasone (Neill and Hunt, 1995)
that prevent the development of ECM have proven
ineﬀective in humans (Hoﬀman et al. 1988; van
Hensbroek et al. 1996). However, with hindsight, it
is perhaps not surprising that treatments that pre-
vent ECM when given prior to the development of
neurological signs may not be able to reverse estab-
lished CM pathologies, which is when they must
be eﬀective in clinical practice. Indeed, ablation of
cytokine signalling, depletion of leukocyte popu-
lations and administration of blocking antibodies are
all able to prevent, but not reverse, ECM (reviewed
by Schoﬁeld and Grau 2005; Good et al. 2005). This
does not necessarily mean, however, that ﬁndings
from experimental models of CM are not relevant to
treatment of CM in humans. Indeed, data showing
that low bioavailability of NO contributes to the
development of ECM in mice are analogous to re-
sults obtained in humans during P. falciparum in-
fection (Gramglia et al. 2006; Yeo et al. 2007, 2008)
and reversal of low NO bioavailability by adminis-
tration of L-arginine or exogenous NO is protective
in mice and humans (Gramglia et al. 2006; Yeo et al.
2007). Combined, these data have led to the current
consideration of L-arginine therapy for phase II
clinical trials in humans with CM. Similarly, the
observation that erythropoietin protects susceptible
mice from ECM (Kaiser et al. 2006) prompted
comparison of erythropoietin levels in the plasma
of uncomplicated and severe malaria patients CM
(Casals-Pascual et al. 2008), leading to erythro-
poietin being considered as a potential adjunct
therapy for CM (Casals-Pascual et al. 2009).
CONCLUSIONS
New adjunct therapies to improve the outcomes of
cerebral malaria are urgently needed. Studies in
humans are severely limited by lack of access to
tissues, the impossibility of carrying out time-course
studies and our inability to infer causality from as-
sociative clinical and epidemiological studies. Whilst
not perfect, the neurological syndrome that develops
in mice infected with P. berghei ANKA recapitulates
most of the physiological, parasitological and im-
munological features of human CM. The ECM
model has allowed the molecular and cellular basis of
CM to be experimentally investigated and explained
and has provided clues that have led to clinical trials
of several potential new therapies. In the future,
the application of increasingly sophisticated exper-
imental techniques, including live imaging of para-
site-host interactions (Wilson et al. 2009; Schaeﬀer
et al. 2009; Ortolano et al. 2009), will allow us to
develop an even greater understanding of the se-
quence of events leading to ECM. We will, for
example, be able to determine whether cerebral in-
ﬂammation precedes or follows pRBC sequestration,
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and whether brain–resident or brain-homing leuko-
cytes are more important for the development
of cerebral pathology, which will inform future
decisions about appropriate immune-modulatory
therapy. The now routine use of ophthalmoscopic
examination of retinal pathology as a diagnostic tool
for CM (White et al. 2009; Beare et al. 2006), which
was ﬁrst described in the experimental P. berghei
ANKA model (Chang-Ling et al. 1992), demon-
strates the importance of translational science in the
understanding of cerebral malaria.
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